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assessment from a hospital perspective based on a retrospective cohort study. SETTING Dutch tertiary
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patients without, and the mean cost difference. For the scenario analyses the outcomes are the potential
cost savings per 1000 patients when a decrease in iCSF leakage would be achieved. RESULTS Mean cost
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main cost driver was hospital stay with a difference of 8.5 days. A 25% incidence reduction would result in
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tion of -€653 025 (95% CI, -€1 204 243 to -€169 120) per 1000 patients could be achieved if iCSF leakage
would be reduced with 75% in all patients, with 72 cases of iCSF leakage avoided. CONCLUSIONS
Postoperative iCSF leakage after intradural cranial surgery increases healthcare costs significantly and
substantially. From a health economic perspective preventative measures to avoid iCSF leakage should
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ABSTRACT
Objectives We aim to quantify the cost difference 
between patients with incisional cerebrospinal fluid (iCSF) 
leakage and those without after intradural cranial surgery. 
Second, the potential cost savings per patient when a 
decrease in iCSF leakage rate would be achieved with and 
without added costs for preventative measures of various 
price and efficacy are modelled.
Design Health economic assessment from a hospital 
perspective based on a retrospective cohort study.
Setting Dutch tertiary referral centre.
Participants We included 616 consecutive patients 
who underwent intradural cranial surgery between 
1 September 2017 and 1 September 2018. Patients 
undergoing burr hole surgery or transsphenoidal surgery, 
or who died within 1 month after surgery or were lost to 
follow- up were excluded.
Primary and secondary outcome measures Outcomes 
of the cost analysis include a detailed breakdown of 
mean costs per patient for patients with postoperative 
iCSF leakage and patients without, and the mean cost 
difference. For the scenario analyses the outcomes are the 
potential cost savings per 1000 patients when a decrease 
in iCSF leakage would be achieved.
Results Mean cost difference between patients with 
and without iCSF leakage was €9665 (95%CI, €5125 
to €14 205). The main cost driver was hospital stay 
with a difference of 8.5 days. A 25% incidence reduction 
would result in a mean cost saving of −€94 039 (95% CI, 
−€218 258 to −€7077) per 1000 patients. A maximum 
cost reduction of −€653 025 (95% CI, −€1 204 243 to 
−€169 120) per 1000 patients could be achieved if iCSF 
leakage would be reduced with 75% in all patients, with 
72 cases of iCSF leakage avoided.
Conclusions Postoperative iCSF leakage after intradural 
cranial surgery increases healthcare costs significantly 
and substantially. From a health economic perspective 
preventative measures to avoid iCSF leakage should be 
pursued.
INTRODUCTION
Cerebrospinal fluid (CSF) leakage is one 
of the most common complications after 
neurosurgical intervention. The incidence of 
CSF leakage after intradural cranial surgery 
reported in the literature is 8% on average 
and depends on location of the surgery, indi-
cation of the surgery and patient- related risk 
factors.1 CSF leakage- related complications 
include wound infection and meningitis, and 
may necessitate prolonged hospital admis-
sion, external CSF drainage or reoperation. 
Therefore, CSF leakage is not only associ-
ated with substantial morbidity, but also with 
increased healthcare costs as well.1 Groten-
huis found that the total extra cost of CSF 
leakage is approximately €12 000 for intra-
dural cranial surgery, looking at the direct 
medical costs.2 Previous research, however, 
lacks specification of the main cost drivers 
and analysis of costs for specific treatment 
modalities for CSF leakage. Both the health 
and economic consequences of CSF leakage 
emphasise the importance of prevention of 
CSF leakage.
Strengths and limitations of this study
 ► To our knowledge, this is the largest cost analysis 
providing a detailed breakdown of costs for incision-
al cerebrospinal fluid (iCSF) leakage after intradural 
cranial surgery.
 ► An advantage of the method applied in this study 
is the adaptability of the transparent model to other 
settings.
 ► One limitation of our approach is the effect of initial 
surgery costs on the results of our analyses.
 ► Although, this analysis contains the largest patient 
population in an economic evaluation of iCSF leak-
age, the number of patients in the individual cate-
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Yet, preventative measures to reduce CSF leakage inci-
dence may require financial input as well. Neurosurgeons 
closing themselves instead of residents, the use of devices, 
or increased operating room time because of a more 
precise closing technique to prevent CSF leakage may 
all lead to increased healthcare costs. Cost- benefit anal-
yses of preventative strategies to reduce CSF leakage are 
lacking in the current body of literature.
In an increasingly cost aware healthcare system, finan-
cial implications of complications and their prevention 
are of great importance in deciding, which preventative 
strategies to pursue. Therefore, the health economic 
consequences should be considered as well when evalu-
ating the efficacy of preventative strategies to avoid iCSF 
leakage.
The primary objective of the current study is to quan-
tify the difference in healthcare consumption and asso-
ciated costs between patients with CSF leakage after 
intradural cranial surgery and those without postopera-
tive CSF leakage. The secondary objective is to quantify 
the economic effect per patient when a decrease in CSF 
leakage rate and related complications would be achieved 
using preventative measures that may require financial 
input.
METHODS
This cost analysis was performed from a hospital perspec-
tive, including detailed healthcare consumption of 
every individual patient. This study uses direct medical 
costs, without taking into account health insurance 
reimbursement.
Clinical data from a single centre were retrieved from 
previously collected retrospective international multi-
center database (unpublished raw data). All consecu-
tive adult patients undergoing intradural cranial surgery 
between 1 September 2017 and 1 September 2018 at 
the University Medical Center Utrecht were included. 
Patients who died within 1 month after surgery or were 
lost to follow- up were excluded, as for these patients there 
was insufficient certainty regarding the occurrence of the 
primary outcome measure (CSF leakage) introducing 
bias into the analysis and healthcare resources used 
during follow- up. Patients undergoing burr hole surgery 
or transsphenoidal surgery were excluded, as they repre-
sent separate patient categories with specific healthcare 
utilisation.
The following surgical characteristics had been 
collected: indication, urgency level, reoperation (yes/no), 
location of craniotomy (supratentorial or infratentorial), 
use of dural substitute and use of a dural sealant. Patient 
characteristics retrieved from the database included: age, 
sex, preoperative dexamethasone use, history of radiation 
therapy, diabetes, body mass index and smoking.
CSF leakage was defined as incisional cerebrospinal 
fluid (iCSF) leakage (either clinically diagnosed or 
confirmed through Beta- 2 transferrin test) and did not 
include pseudomeningocele. Postoperative infection 
included superficial wound infection and deep wound 
infection and/or meningitis requiring treatment. The 
type of treatment was reviewed when iCSF leakage 
occurred. The treatment was divided into three catego-
ries: conservative treatment, external drainage placement 
and operative wound revision. Conservative treatment 
consisted of pressure bandage for wound compression 
and/or additional suture placement. First, a cost anal-
ysis was performed based on clinical and detailed cost 
data. This cost analysis was followed by scenario analyses 
to investigate the effect of reduction of iCSF leakage on 
health economic outcomes. A decision tree was used to 
combine the afore- mentioned cost analysis and the inci-
dence rates of complications.
Cost analysis
Healthcare resources consumed by eligible patients from 
30 days prior to 180 days after surgery were retrieved 
from medical records. Costs included readmissions and 
considers all- cause healthcare utilisation. Unit prices 
were retrieved from the Dutch Healthcare Authority 
(Nederlandse Zorgautoriteit), the cost manual of the 
National Healthcare Institute (Zorginstituut Nederland) 
and literature research and linked to the corresponding 
healthcare activities.3 4 The costs for an external ventricle 
drain and external lumbar drain and dural sealants were 
based on the existing literature and local prices.5 Costs for 
cranial surgery and reoperation were determined based 
on operating room time multiplied by cost per minute 
(€10.59).6 All costs are presented in 2018 Euros.
Outcomes of the cost analysis included a detailed break-
down of mean costs per patient for patients with postop-
erative iCSF leakage and patients without. Different costs 
were divided into categories; outpatient visits, diagnostics, 
primary surgery, expensive drugs (eg, chemotherapy for 
patients with brain tumour), clinical admissions, other 
costs (eg, physiotherapy and dietetics), leakage treatment 
and sealant costs.
As well as the total healthcare costs for patients with 
CSF leakage stratified by treatment; reoperation, drain 
(external lumbar drain and external ventricle drain), 
reoperation and drain, and/or conservative treatment 
(including pressure bandage and additional sutures). 
Difference between groups was tested with Mann- Whitney 
U test since data were not normally distributed.
Scenario analysis
Model development
A decision tree was developed (online supplemental 
material 1) outlining intradural cranial surgery and the 
occurrence of complications, including iCSF leakage. 
This decision tree allows the quantification of the room 
for improvement in scenario analyses by adapting prob-
abilities of individual events. This is achieved by multi-
plying the probability of a patient qualifying for a certain 
subgroup by the healthcare costs associated with these 
subgroups, online supplemental material 1 outlines the 
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healthcare costs. Outliers can impact outcomes signifi-
cantly. To account for input parameter uncertainty distri-
butions were fitted, beta distributions for probabilities 
and gamma distributions for costs. A probabilistic analysis 
with a Monte Carlo simulation with 10 000 iterations was 
used to determine model outcomes and ranges.
Scenario analyses
Scenario analyses were performed to determine the 
health economic effects of reduction of iCSF leakage. 
Three different scenarios were applied to gain more infor-
mation on the possible benefits of CSF reduction with 
various preventative strategies. (I) The iCSF leakage inci-
dence use was decreased with 25% steps between 0% and 
75%. (II) The iCSF leakage incidence was reduced and 
weighted against varying costs of potential interventions 
of variable efficacy. (III) The first two scenario’s applied 
for subgroups with different risk of iCSF leakage (supra-
tentorial surgery and infratentorial surgery). Outcomes 
of the scenario analyses were presented as difference in 
costs and number of iCSF leakage cases avoided per 1000 
patients was calculated as well as the number needed 
to treat (NNT). To determine parameter influence 
on the outcome of the scenarios, a deterministic sensi-
tivity analysis was performed and a tornado diagram was 
constructed.
RESULTS
In total, 616 consecutive patients were included in this 
study. Table 1 provides an overview of the patient charac-
teristics. The mean age of patients was 53.5 (±15.8) years. 
The most common indication for surgery was tumour 
resection; 399 patients (64.8%) and most patients had 
a supratentorial approach; 517 (83.9%). A total of 59 
patients had postoperative iCSF leakage (9.6%).
Cost per patient and detailed breakdown costs
Average cost per patient and a detailed breakdown of 
costs are included for all of the 616 patients. In table 2, 
the average costs per patient with and without iCSF 
leakage are outlined. Five out of seven cost categories 
were higher for patients with iCSF leakage compared with 
patients without iCSF leakage. Costs for external ventricle 
drain, external lumbar drain and reoperation were cate-
gorised under treatment costs in table 2.
Difference in costs between patients without iCSF 
leakage and with iCSF leakage was €9665 (95% CI, 
€5125 to €14 205). Total average healthcare costs for 
patients without iCSF leakage was €20 498 (95% CI, €19 
183 to €21 813) compared with €30 163 (95% CI, €23 
654 to €36 672) for patients with iCSF leakage (table 2). 
When comparing costs incurred starting from the day of 
primary surgery (days 0–180), costs were €17 759 (95% 
CI, €16 497 to €19 021) for patients without iCSF leakage 
and €28 105 (95% CI, €21 695 to €34 515) for patients 
with iCSF leakage.
The main reason for the difference in cost, over both 
the total time and the postoperative time, was the signifi-
cant difference in length of hospital stay, for which costs 
are categorised as clinical admissions. Difference in 
length of stay (LOS) was 8.5 days (95% CI, 5.3 to 11.7). 
For patients without incisional leakage, LOS was 12.8 days 
(95% CI, 11.9 to 13.8) and for patients with iCSF leakage 
LOS was 21.3 days (95% CI, 16.6 to 26.1). Furthermore, 
the incidence of secondary complications was significantly 
higher in the iCSF group. Highest costs among subgroups 
were found for patients with deep wound infection and/
or meningitis (€39 323 to €57 862). Patients without 
additional complications had the lowest costs among all 
subgroups (€19 050 to €26 797) (table 3).
For supratentorial surgery, there was a significant cost 
difference between patients with iCSF leakage (€20 180, 
Table 1 Patient characteristics
All patients (N=616) No iCSF leakage (N=557) iCSF leakage (N=59) P value
Male; N (%) 296 (48.1) 267 (49.7) 29 (49.2) 0.859
Age; years (±SD) 53.5 (±15.8) 53.6 (±15.8) 52.6 (±16.2) 0.656
BMI; (±SD) 26.1 (±6.9) 25.9 (±6.9) 27.8 (±6.4) 0.036
Indication; N (%) 0.474
  Tumour 399 (64.8) 356 (63.9) 43 (72.9)
  Vascular 121 (19.6) 113 (20.3) 8 (13.6)
  Epilepsy 62 (10.1) 57 (10.2) 5 (8.5)
  Trauma 22 (3.6) 19 (3.4) 3 (5.1)
  Other 12 (1.9) 12 (2.2) 0 (0.0)
Tentorial approach; N (%) <0.001
  Supratentorial 517 (83.9) 481 (86.4) 36 (61.0)
  Infratentorial 99 (16.1) 76 (13.6) 23 (39.0)
P values smaller than 0.05 are considered significant.
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± €14 504) and those without (€31 219 ± €25 224). For 
infratentorial surgery, patients with iCSF leakage had 
a mean cost of €28 510 (± €25 057) as compared with 
€22.512 (± €22 369) for patients without iCSF leakage. 
This difference was not statistically significant (table 3).
In the group of patients with postoperative iCSF leakage 
(N=59), 18 patients received conservative treatment, 7 
patients required reoperation, 26 patients were treated 
with an external CSF drain and 8 patients required reop-
eration and a drain. In the group of patients treated 
conservatively, 10/18 had CSF leakage once or two times. 
All other patients with CSF leakage had continuous 
leakage. Table 4 shows the total healthcare costs and LOS 
for patients with iCSF leakage stratified per treatment 
modality. Lowest costs were found for the 18 patients 
who were treated conservatively (€21 046 (±€11 433)). 
Highest costs were found for the seven patients requiring 
reoperation; €36 117 (± €45 056). Longest LOS was 
for patients requiring reoperation and drain; 26.5 days 
(±17.6 days). There was no statistically significant differ-
ence in LOS or costs between patients who were treated 
conservatively and those who underwent reoperation. 
Patients who were treated with external CSF drainage or 
reoperation and external CSF drainage combined had 
significantly longer LOS and higher costs compared with 
patients who were treated conservatively. No significant 
differences in LOS or costs were found between invasive 
treatment modalities.
Scenario analyses
Table 5 presents an overview of the outcomes of scenario 
analysis I and III.
Figure 1 shows the potential cost savings per patient 
when a decrease in iCSF leakage would be achieved. A 
maximum cost reduction of −€653 025 (95% CI, −€1 204 
243 to −€169 120) per 1000 patients could be achieved if 
iCSF leakage would be reduced with 75%. The number 
of cases avoided would be 72. The NNT in this scenario is 
14. For supratentorial surgery reduction of iCSF leakage 
with 25%–75% would lead to significant cost reduction 
and a maximum of 53 cases of iCSF leakage avoided. For 
infratentorial surgery there is a trend towards substantial 
cost savings for reduction rates between 25% and 75%; 
however, this is not significant.
If costs of potential preventative strategies are added to 
accomplish iCSF leakage (scenario II and III) our model 
shows cost reduction for measures at a price of €250 per 
patient at an iCSF leakage reduction of 50%–75% in all 
patients and both subgroups. Preventative strategies at a 
price of €500 euro per patient only lead to cost savings in 
all patients and supratentorial cases if they reduce iCSF 
leakage with 75%. For infratentorial cases, this scenario 
results in cost savings at a 50% reduction as well. Preven-
tative strategies that cost €750 per patient lead to cost 
reduction only when applied in infratentorial cases with 
an iCSF leakage reduction of 75% (figure 2).
The deterministic sensitivity analysis showed that 




































































































































































































































































































































































































































































































































































































































































































































































































































































5van Lieshout C, et al. BMJ Open 2021;11:e052553. doi:10.1136/bmjopen-2021-052553
Open access
outcomes was costs for patients without iCSF leakage 
and an infratentorial approach. Lowest influence was 
found for the incidence of iCSF leakage in infratentorial 
patients (figure 3).
DISCUSSION
There is a substantial and significant cost difference of 
€9665 between patients with postoperative iCSF leakage 
after intradural cranial surgery and those without. The 
average healthcare cost for cranial intradural surgery 
ranges between €20 498 for patient without iCSF leakage 
and €36 117 for patients with reoperation, which was the 
most expensive. A maximum cost reduction of −€653 025 
(95% CI, −€1 204 243 to −€169 120) per 1000 patients 
could be achieved if iCSF leakage would be reduced with 
75% in all patients.
Our model shows that reducing leakage rates could 
lead to substantial cost reduction, even if financial input 
is required. However, whether the use of preventative 
measures that require financial input in all patients or a 
subgroup of patients at risk results in cost savings depends 
on their price and efficacy. Because of the higher risk of 
iCSF leakage in infratentorial surgery, more expensive 
preventative measure of a certain efficacy could still lead 
to cost savings in this subgroup, when they do not for the 
total population.
To our knowledge, this is the largest cost analysis 
providing a detailed breakdown of costs for iCSF leakage 
after intradural cranial surgery. Furthermore, it is the first 
study applying a model to calculate the health economic 
effects of improved preventative measures. An advantage 
of the method applied in this study is the adaptability of 
the transparent model to other settings. If other hospi-
tals are aware of their leakage rate and healthcare costs, 
this method could be used to estimate possible future cost 
savings, for example with improved sealants.
One limitation of our approach is the effect of initial 
surgery costs on the results of our analyses. Despite this 
being the most comprehensive method of taking into 
account all associated costs, it may be the case that part 
of the cost difference is driven by the initial surgery, 
as complex and longer surgeries are more expensive. 
Second, we have collected healthcare consumption in a 
single centre. There is thus a theoretical risk of missing 
the costs of patients that may have received follow- up 
treatment elsewhere, without this being communicated 
to the primary centre. As patients with loss to follow- up 
were excluded from the initial database and treatment 
of complications in a different centre is unusual, we do 
not believe this has affected the outcomes of the current 
study.
Thereby, although this analysis contains the largest 
patient population in an economic evaluation of iCSF 
leakage, the number of patients in the individual catego-
ries for secondary complications and treatment modal-
ities remains low. It is, therefore, difficult to interpret 
cost differences for specific secondary complications in 
detail. In these limited numbers of cases, heterogeneity of 
patients could be the main difference between those with 
iCSF leakage and those without. Results of the compari-
sons between the different treatment modalities should 
be interpreted with some caution as well, for the same 
reason. Especially, the subgroup of patients who under-
went reoperation is limited in size and has large SD of 
both the LOS and the costs. Furthermore, these limited 
subgroups led to larger uncertainty around the scenario 
analyses modelling the potential health economic effects 
of iCSF leakage reduction, especially for the infratento-
rial subgroup. Another limitation of the scenario analyses 
is the linear reduction in iCSF leakage, which assumes 
that iCSF leakage can be prevented with a certain effi-
cacy across the total population. It may, however, be the 
case that for certain subgroups iCSF leakage cannot be 
avoided with preventative measures.
These results are based on healthcare consumption 
and costs of one centre in the Netherlands. Therefore, 
applying these results to different countries is chal-
lenging. Differences in clinical practice and prices, for 
Table 3 Average total healthcare costs per patient for different subgroups based on approach and complication
No iCSF leakage (N=557) iCSF leakage (N=59)
P valueN Mean SD N Mean SD
Supratentorial 481 €20 180 €14 504 36 €31 219 €25 224 0.014
No complications 457 €19 050 €12 844 18 €26 797 €19 547 0.015
Superficial wound infection 10 €31 616 €32 380 10 €30 448 €22 020 0.926
Deep wound infection and/or meningitis 14 €48 881 €24 918 8 €42 130 €37 982 0.557
Infratentorial 76 €22 512 €22 369 23 €28 510 €25 057 0.276
No complications 73 €21 883 €22 383 16 €25 163 €16 561 0.574
Superficial wound infection 2 €27 804 €11 027 2 €28 248 €16 988 0.978
Deep wound infection and/or meningitis 1 €57 862 – 5 €39 323 €50 566 0.755
P values smaller than 0.05 are considered significant.
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instance, may influence the effects observed in this study 
considerably.7 It is thus recommended that data on cost 
prices and resource use should be obtained from or 
adapted to the setting of interest.7 Furthermore, baseline 
risk should be location specific, whereas treatment effect 
may be more generalisable.7 Although, larger differences 
are to be expected between the healthcare systems across 
continents, even within western Europe economic anal-
yses of medicines vary significantly.7
The additional healthcare costs for patients with inci-
sional CSF leakage in this study are comparable to those 
found by Grotenhuis in the Netherlands, who found 
a cost difference of approximately €12 000, for cranial 
surgery including transsphenoidal procedures.2 Our 
study includes all healthcare resources consumed within 
a predefined time frame, whereas Grotenhuis based 
calculations on certain cost categories only. Another study 
from Germany by Piek et al calculated cost differences 
between patients with and without CSF leakage in detail 
and found a comparable result of €11.420.8 Their study, 
however, also included subcutaneous CSF collections as 
CSF leaks, and it has a limited sample size of 168 patients 
(of which only three had percutaneous CSF leaks).8
The breakdown of costs shows that clinical admis-
sion is the main cost driver for the difference between 
patients with and without iCSF leakage. Patients with 
iCSF leakage have higher risk of infection or meningitis.9 
These complications may further explain the cost differ-
ence between patients with and without iCSF leakage as 
they require prolonged clinical admission. These results 
are in line with the study of Parikh et al that identified 
increased LOS and the association of CSF leakage with 
secondary complications such as meningitis as the main 
reasons for increased healthcare costs after transsphe-
noidal surgery.10
Additionally, the costs for interventional treatment 
of iCSF leakage are a substantial cost driver, consid-
ering that patients who can be managed conservatively 
have total average costs that are comparable to patients 
without iCSF leakage. In the group of patients managed 
conservatively, though, 10/18 patients (55.6%) did not 
have continuous iCSF leakage, but incisional leakage 
that occurred once or twice, suggestive of a subcuta-
neous pocket that has discharged. All patients that had 
to be managed with invasive treatment had continuous 
iCSF leakage. Patients treated with an external CSF drain 
have significantly longer LOS and higher costs compared 
with those treated conservatively. Contrary to Parikh et 
al we did not find shorter LOS in patients treated with 
reoperation compared with those treated with external 
CSF drainage only.10 This may imply that reoperation as 
a treatment for iCSF leakage is performed sooner after 
endoscopic endonasal surgery than after craniotomy. An 
advantage of reoperation compared with external CSF 
drainage is the quick return to mobilisation as opposed 
to bedrest required during external CSF drainage. This 
is not reflected in a difference in LOS between these 
patients in our population, however. Besides a delay in 
surgical treatment, other factors related to recovery such 
as comorbidity may explain why LOS is similar for these 
treatment modalities.
This study confirms that from a health economic 
perspective, iCSF leakage should be reduced. Improved 
preventative strategies reducing the iCSF leakage rate, 
even though they may add to the overall healthcare 
costs per patient, could be beneficial from an economic 
standpoint. Furthermore, increased understanding 
of risk factors for iCSF leakage and associated costs 
may contribute to improving the indication for use of 
currently available and future methods of augmented 
dural closure. Considering that conservative treatment 
for continuous iCSF leakage is rarely effective, early 
interventional treatment for this group is recommended. 
Figure 1 Potential costs savings per patient with a decrease 
in incisional cerebrospinal fluid leakage.
Figure 2 Cost difference per patient, per change in 
incidence and cost for preventative measure.
Figure 3 Tornado diagram indicting the influence of the 
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Furthermore, methods that shorten LOS for patients with 
external CSF drains should be investigated. Our model of 
the health economic effects of iCSF leakage and potential 
cost savings of improved preventative strategies should 
be applied to different healthcare settings to evaluate 
the cost difference and potential cost savings location 
specifically to assist physicians and healthcare managers 
in decision- making regarding preventative strategies to 
avoid iCSF leakage in their situation.
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